Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
MingSight Pharmaceuticals General Information
MingSight Pharmaceuticals develops next-generation selective protein kinase C beta inhibitors. Its lead candidate MS‑553 has shown promising proof-of-mechanism data with strong efficacy and safety signals in ongoing Phase I/II trials targeting chronic lymphocytic leukemia/small lymphocytic lymphoma and diabetic macular edema. The compound aims to address shortcomings of previous pan-PKC inhibitors by improving selectivity, safety profile, and pharmacokinetics. Early results have demonstrated significant activity where prior approaches failed.[3][4]
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
MS-553
Phase 2Key Partnerships
Kaitai Capital led recent financing round; collaboration with Jiangsu MingSight Relin Pharmaceutical for China-based development/trials.[3][5]
MingSight Pharmaceuticals Funding
No funding data available
To view MingSight Pharmaceuticals's complete valuation and funding history, request access »